隐匿性与经典型脉络膜新生血管抗VEGF治疗五年真实世界结局
基于Fight Retinal Blindness!项目数据库,回顾性分析1929只眼(隐匿性1196只、微经典型289只、 predominantly经典型444只)接受抗VEGF治疗的5年结局。隐匿性CNV基线视力更高且5年时视力仍更优,但多因素模型校正基线视力后CNV类型对最终视力无显著影响;经典型CNV更早失活且整体活动性更低,各组注射次数相似。
要点
- 隐匿性CNV基线及5年视力均优于经典型CNV。
- 校正基线视力后,CNV类型对最终视力无显著影响。
- 经典型CNV更早失活且整体活动性更低,注射次数组间相似。
核心结论
- 隐匿性CNV眼整体视力优于其他CNV类型,但校正基线视力后最终视力差异不显著。
- 五年结局和治疗模式未受病灶类型影响。
研究设计与样本
- 前瞻性设计观察数据库的回顾性分析,纳入2007年1月至2012年12月起始抗VEGF治疗、初治的隐匿性或微/ predominantly经典型CNV眼。
- 共分析1730名受试者的1929只眼,其中隐匿性1196只、微经典型289只、 predominantly经典型444只。
主要发现
- 各组视力变化相似,5年时隐匿性CNV眼视力仍优于其他CNV类型。
- 多因素模型中年龄、病灶大小和基线视力显著影响最终视力,而CNV类型无显著影响。
- predominantly经典型CNV更早失活且整体活动性低于其他CNV类型,各组注射次数相似。
临床怎么用
- 真实世界中抗VEGF治疗nAMD时,CNV病灶类型不影响五年视力结局和治疗模式。
- 经典型CNV可能更早失活且活动性更低,但注射次数与隐匿性CNV相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare 5-year real-world outcomes of eyes with classic and occult choroidal neovascularization (CNV) treated with anti-vascular endothelial growth factor (anti-VEGF) injections. DESIGN: Retrospective analysis from a prospectively designed observational database. METHODS: Treatment-naïve eyes diagnosed with occult or minimally or predominantly classic CNV that commenced anti-VEGF treatment between January 2007 and December 2012 were identified from a registry of neovascular age-related macular degeneration (nAMD) treatment outcomes. Baseline characteristics, visual acuity (VA) at 5 years, change in VA, time to first inactivation, number of injections, and proportion of visits graded with active nAMD over the 5 years were compared between the 3 groups. RESULTS: A total of 1929 eyes from 1730 subjects (1196 occult, 289 minimally classic, and 444 predominantly classic CNV) were analyzed. Baseline VA (mean [standard deviation]) was higher in occult CNVs (56.9 [17.4] letters) than in minimally (52.9 [19.7] letters) and predominantly (49.1 [19.9] letters) classic CNVs (P = .003 and P < .0001, respectively). VA change was similar across the groups. At 5 years eyes with occult CNVs still had better VA than other CNVs. Age, lesion size, and baseline VA, but not CNV type, significantly affected final VA in the multivariate model. Predominantly classic CNVs became inactive sooner and were overall less active than other CNV types. The number of injections received was similar across the groups. CONCLUSIONS: Eyes with occult CNVs had overall a better VA than other CNVs. The difference in final VA was not significant after adjusting for baseline VA. Five-year outcomes and treatment patterns were not affected by the lesion type.
引用
- Invernizzi A, Nguyen V, Teo K, et al. Five-Year Real-World Outcomes of Occult and Classic Choroidal Neovascularization: Data From the Fight Retinal Blindness! Project. Am J Ophthalmol. 2019. PMID: 30862501. doi:10.1016/j.ajo.2019.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。